Hanall Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Hanall Biopharma has a total shareholder equity of ₩186.2B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩239.7B and ₩53.5B respectively. Hanall Biopharma's EBIT is ₩1.7B making its interest coverage ratio -1.5. It has cash and short-term investments of ₩56.5B.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | -1.5x |
| Cash | ₩56.50b |
| Equity | ₩186.22b |
| Total liabilities | ₩53.53b |
| Total assets | ₩239.75b |
Recent financial health updates
No updates
Recent updates
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13
Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Financial Position Analysis
Short Term Liabilities: A009420's short term assets (₩113.6B) exceed its short term liabilities (₩37.7B).
Long Term Liabilities: A009420's short term assets (₩113.6B) exceed its long term liabilities (₩15.9B).
Debt to Equity History and Analysis
Debt Level: A009420 is debt free.
Reducing Debt: A009420 had no debt 5 years ago.
Debt Coverage: A009420 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A009420 has no debt, therefore coverage of interest payments is not a concern.